Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Details emerge from incident that led Seagen’s CEO to take a leave of absence 

By Brian Buntz | May 12, 2022

SeagenSeagen (Nasdaq:SGEN) has tapped a law firm to lead an investigation into its CEO Clay Siegall, who was charged with misdemeanor assault against his wife on April 23.

Siegall maintains his innocence.

A police report related to the incident reported that Siegall’s wife called 911 after he allegedly forced her to the ground.

Siegall was later charged with fourth-degree domestic violence, according to police reports obtained by Endpoints News.

Siegall’s wife also filed a temporary restraining order against him. The couple is going through divorce proceedings.

The police report alleges that Siegall (61) pushed his wife Nellie to the ground and dragged her along the floor, causing bruises and abrasions.

Founded in 1997, Bothell, Washington-based Seagen is a leading biotechnology company focused on antibody-drug conjugates. Its 2021 revenues were $1.6 billion.

Siegall is a co-founder of the company.

Following the recent allegations, Seagen has installed its chief medical officer, Dr. Roger Dansey, to assume the role of interim CEO. Dansey has worked at the company since 2018.

Siegall’s future role at the company is uncertain.

Nancy Simonian, chair of Seagen’s nominating and corporate governance committee, said the company is “treating these allegations with the utmost seriousness.”

“At this time, the facts are still uncertain, and our decisions will be guided by the outcome of our investigation,” Simonian continued.


Filed Under: Drug Discovery
Tagged With: Clay Siegall, Seagen
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Black Diamond Therapeutics
Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50